Get the Stockscreener App
0.4857
0.56%
0.0027
Plus Therapeutics Inc stock is traded at $0.4857, with a volume of 5.24M.
It is up +0.56% in the last 24 hours and up +14.28% over the past month.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
See More
Previous Close:
$0.483
Open:
$0.4715
24h Volume:
5.24M
Relative Volume:
0.18
Market Cap:
$29.38M
Revenue:
-
Net Income/Loss:
$-12.89M
P/E Ratio:
-0.192
EPS:
-2.53
Net Cash Flow:
$-11.95M
1W Performance:
-22.65%
1M Performance:
+14.28%
6M Performance:
-59.52%
1Y Performance:
-66.03%
1-Day Range:
$0.47
$0.525
1-Week Range:
$0.4528
$0.5892
52-Week Range:
$0.1634
$2.3099
Plus Therapeutics Inc Stock (PSTV) Company Profile
Name
Plus Therapeutics Inc
Sector
Industry
Phone
737.255.7194
Address
4200 MARATHON BLVD., AUSTIN, TX
Compare PSTV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PSTV
Plus Therapeutics Inc
|
0.4857 | 32.43M | 0 | -12.89M | -11.95M | -2.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-25 | Initiated | D. Boral Capital | Buy |
| Jan-25-21 | Initiated | Ladenburg Thalmann | Buy |
| Oct-16-20 | Initiated | Maxim Group | Buy |
Plus Therapeutics Inc Stock (PSTV) Latest News
Plus Therapeutics Inc. Added to Custom Quant Screener Today2025 Growth vs Value & Consistent Return Strategy Ideas - beatles.ru
Plus Therapeutics Presents Positive ReSPECT-LM Clinical Trial Results of REYOBIQ in Leptomeningeal Metastases - MarketScreener
Plus Therapeutics shares rise 2.61% premarket after reporting stockholders' equity of $3 million, satisfying Nasdaq Listing Rule. - AInvest
How Plus Therapeutics Inc. stock performs during market volatilityVolume Spike & Fast Entry High Yield Tips - beatles.ru
Plus Therapeutics presents positive Respect-LM trial results of Reyobiq in leptomeningeal metastases - MarketScreener
Plus Therapeutics price target lowered to $3 from $4 at Maxim - TipRanks
Plus Therapeutics presents results from ReSPECT-LM Phase 1 trial - TipRanks
Plus Therapeutics Presents Positive ReSPECT-LM Clinical Trial Results of REYOBIQ™ in Leptomeningeal Metastases | PSTV Stock News - GuruFocus
Plus Therapeutics Reports Promising Efficacy and Safety Data for REYOBIQ in Leptomeningeal Metastases Clinical Trial - Quiver Quantitative
Plus Therapeutics Presents Positive ReSPECT-LM Clinical Trial Results of REYOBIQ™ in Leptomeningeal Metastases - GlobeNewswire
87% Clinical Response: Plus Therapeutics' REYOBIQ Breakthrough Shows Promise for Terminal Brain Cancer Patients - Stock Titan
Why Did Plus Therapeutics Plunge 17.83% After Earnings? - AInvest
Plus Therapeutics Misses on Revenue and Costs: Earnings Drag Stock and Signal Weak Short-Term Prospects - AInvest
Plus Therapeutics Q2 Earnings Miss Sparks Mixed Market Reaction - AInvest
What is Plus Therapeutics Inc. s P E ratio telling us2025 Momentum Check & Verified Technical Trade Signals - classian.co.kr
Why Plus Therapeutics Inc. stock attracts strong analyst attention2025 Market WrapUp & Technical Entry and Exit Tips - thegnnews.com
Plus Therapeutics announces $1.6 million advance payment from CPRIT - MSN
Plus Therapeutics Posts Q2 2025 Loss as Revenue Falls Short, Sparking Mixed Market Reactions - AInvest
Will Plus Therapeutics Inc. Recover After Recent Decline2025 Institutional Moves & Real-Time Volume Analysis Alerts - newsyoung.net
Optimistic Buy Rating for Plus Therapeutics Driven by Strategic Financial Positioning and Clinical Advancements - TipRanks
Plus Therapeutics Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Plus Therapeutics Approves Key Proposals at Annual Meeting - MSN
Biotech Valuation Dilemmas: Can Plus Therapeutics (PSTV) Navigate the Grant-to-Product Transition? - AInvest
Assessing Plus Therapeutics (PSTV) as a High-Risk, High-Reward Play in CNS Oncology Innovation - AInvest
Plus Therapeutics Reports Stockholders’ Equity in Excess of - GlobeNewswire
Plus Therapeutics' Nasdaq Compliance Victory: A Strategic Win in the High-Growth CNS Oncology Sector - AInvest
Unlocking the Value of Plus Therapeutics: A Strategic Buy Case Amid Clinical Breakthroughs and Undervaluation - AInvest
Plus Therapeutics shares fall 12.42% after-hours following a new issue of shares. - AInvest
The Oncology Institute, Inc. shares rise 1.06% after-hours following Plus Therapeutics' positive CNSide CSF Assay data presentation. - AInvest
Plus Therapeutics Maintains Buy Rating with $3.00 Price Target - AInvest
Colorectal Cancer Pipeline 2025: MOA, ROA, and Clinical Trial Insights Explored by DelveInsight | Novartis, Pharma Oncology, Purple Biotech Ltd, Plus Therapeutics, Processa Pharma, Shanghai Henlius - Barchart.com
Plus Therapeutics Reports $3M in Stock Equity - Baystreet.ca
Plus Therapeutics (PSTV) Falls After Mixed Q2 Results and Secondary Offering - GuruFocus
Plus Therapeutics meets Nasdaq equity requirement to maintain listing By Investing.com - Investing.com Nigeria
Plus Therapeutics meets Nasdaq equity requirement to maintain listing - Investing.com
Plus Therapeutics Reports Stockholders' Equity in Excess of $2.5 million in Compliance with Nasdaq Equity Requirements | PSTV Stock News - GuruFocus
Plus Therapeutics Reports Satisfactory Equity, Avoids Nasdaq Delisting - AInvest
Plus Therapeutics Reports Stockholders’ Equity in Excess of $2.5 million in Compliance with Nasdaq Equity Requirements - MarketScreener
$3M Equity Achievement: Plus Therapeutics CNS Cancer Drug Developer Maintains Nasdaq Listing Status - Stock Titan
Buy Rating for Plus Therapeutics: Strategic Market Launch and Promising Financial Outlook - TipRanks
We're Keeping An Eye On Plus Therapeutics' (NASDAQ:PSTV) Cash Burn Rate - Yahoo Finance
Plus Therapeutics 2025 Q2 Earnings Remarkable Turnaround in Net Income - AInvest
Plus: Q2 Earnings Snapshot - Norwalk Hour
Plus Therapeutics Posts Q2 Profit Jump - AOL.com
Plus Therapeutics Reports Strong Q2 2025 Results - TipRanks
Plus Therapeutics (PSTV) Reports Q2 Loss, Misses Revenue Estimates - MSN
Plus Therapeutics Posts Q2 Profit Jump, Reversing Last Year's Loss - AInvest
Plus Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Plus Therapeutics Awaits Nasdaq Compliance Confirmation - TipRanks
Plus Therapeutics Reports Second Quarter Financial Results and Recent Business Highlights | PSTV Stock News - GuruFocus
Plus Therapeutics Reports Second Quarter Financial Results and Recent Business Highlights - The Manila Times
Plus Therapeutics Inc Stock (PSTV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Plus Therapeutics Inc Stock (PSTV) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hawkins Richard J | Director |
Sep 13 '24 |
Buy |
1.50 |
4,000 |
5,996 |
15,188 |
| Hawkins Richard J | Director |
Sep 12 '24 |
Buy |
1.35 |
6,285 |
8,512 |
11,188 |
| Petersen Greg | Director |
Sep 11 '24 |
Buy |
1.35 |
12,500 |
16,875 |
48,921 |
| Clowes Howard | Director |
Sep 11 '24 |
Buy |
1.34 |
5,000 |
6,681 |
26,497 |
| HEDRICK MARC H | Chief Executive Officer |
Sep 10 '24 |
Buy |
1.23 |
8,000 |
9,839 |
20,425 |
| Sims Andrew John Hugh MacIntyr | Chief Financial Officer |
Sep 10 '24 |
Buy |
1.27 |
4,098 |
5,204 |
9,815 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):